Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Large Pharma

Takeda Pharmaceutical Co Ltd

+ Add to Watchlist

TKD:GR

46.586 EUR 0.596 1.30%

As of 13:41:31 ET on 03/03/2015.

Snapshot for Takeda Pharmaceutical Co Ltd (TKD)

Open: 46.527 Day's Range: 46.527 - 47.221 Volume: 197
Previous Close: 45.990 52wk Range: 30.975 - 436.557 1-Yr Rtn: +40.76%

Stock Chart for TKD

No chart data available.
  • TKD:GR 47.221
  • 1D
  • 1M
  • 1Y
45.990
Interactive TKD Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for TKD

Current P/E Ratio (ttm) -
Estimated P/E(03/2015) 34.0162
Relative P/E vs. DAX -
Earnings Per Share (JPY) (ttm) -
Est. EPS (JPY) (03/2015) 183.4360
Est. PEG Ratio 2.9970
Market Cap (M EUR) 36,795.20
Shares Outstanding (M) 789.83
30 Day Average Volume 627
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield 2.83%
Cash Dividend (JPY) 90.0000
Dividend Ex-Date 03/27/2015
5 Year Dividend Growth -1.25%
Next Earnings Announcement 05/08/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for TKD

  • Revenue
  • Net Income (M/JPY)
  • Profit Margin (%)

Company Profile & Key Executives for TKD

Takeda Pharmaceutical Co Ltd focuses on the Research & Development, Manufacturing, Sales and Marketing and Import/Export of Pharmaceutical Drugs. The Company focuses on the following core therapeutic areas: Cardiovascular & Metabolic, Oncology, Central Nervous System, Respiratory & Immunology, General Medicine (Gastrointestinal & Genitourinary) and Vaccine.

Yasuchika HasegawaChief Executive OfficerChristophe WeberPresident/COO
Francois-Xavier RogerChief Financial OfficerShinji HondaSenior Managing Director
More Company Profile & Key Executives for TKD

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil